An increased expression of SLC13A5 in the liver has been observed in patients with obesity, NAFLD, and type 2 diabetes as well as in cultured primary hepatocytes treated with glucagon, BaP, or RIF. The gene discussed is SLC13A5; the disease is obesity due to melanocortin 4 receptor deficiency.